Navigation Links
ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin

Speculation that the Food and Drug Administration will give a nod for the generic version of Vancocin caused shares in ViroPharma to dip by about 33 percent. The rumors of the FDA's changed perspective // strengthened after Laura Alvey, a spokeswoman for the F.D.A said in an e-mail message that the agency had "recently revised the bioequivalence recommendations for oral vancomycin from a clinical trial with bioequivalence endpoints to an in vitro method involving dissolution testing."

Vancocin or vancomycin is used exclusively to treat hospital-acquired bacterial infections caused in the lower digestive tract by the bacterium Clostridium difficile. Basically, the FDA's changed stance means that a clinical trial for generic vancomycin might not be necessary if it dissolves at the same rate as Vancocin. ViroPharma has intimated that it has filed a petition to stay the action with the F.D.A and added that it would file many more petitions to support "vigorous opposition to any approach that does not require rigorous scientific methods to demonstrate a rate and extent of drug release to the site of action consistent with good medicine and science." But analysts at Infinium Capital feel that a generic version of Vancocin could be available by early 2008. "Previously, generic manufacturers may not have been interested in developing this therapeutic due to its low revenue potential; however, with the recent sales growth of 133 percent in 2005, Vancocin is now on the radar screen," an analyst at Infinium Capital, Bernadine Leung, said.
'"/>




Page: 1

Related medicine news :

1. Shares Of AVI BioPharma Drops On Reports Of Disappointing Early Drug Trail
2. Sun Pharma Allots Shares Upon Fccbs Conversion
3. Zenotech Issues 20 Lakh Shares to Ranbaxy for Rs 20 Cr
4. FDA Moves In To Check Listeria
5. Genetic Test for Type II Diabetes Moves Closer
6. Inhaled Insulin Study Moves Ahead
7. Looking Towards More Effective Leukemia Treatment
8. Attitude Towards AIDS Patients – Time For A Change
9. Scientists Awarded Appropriately For Contribution Towards Medical Research
10. A Step Towards Unraveling The Schizophrenia And Depression Mystery
11. Are Women Not Hearty Enough Towards Seeking Heart Care?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: